Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10779
Peer-review started: July 12, 2022
First decision: August 4, 2022
Revised: August 17, 2022
Accepted: September 4, 2022
Article in press: September 4, 2022
Published online: October 16, 2022
The co-existence of Waldenström’s macroglobulinemia (WM) with internodal marginal zone lymphoma (INMZL) is rare and often associated with poor prognosis.
We present a Chinese female patient who developed secondary light chain amyloidosis due to WM and INMZL and provides opinions on its systemic treat
A detailed clinical evaluation and active identification of the aetiology are recom
Core Tip: Waldenström's macroglobulinemia (WM) is a lymphoplasmacytic lymphoma, and internodal marginal zone lymphoma (INMZL) is another rare subtype of clinically inertial non-Hodgkin's lymphoma. We report a rare secondary light chain amyloidosis case due to WM and INMZL. We also retrieved related articles indexed in PubMed. Bortezomib-based therapy, including bortezomib, dexamethasone, and zanubrutinb, was administered for two months, and treatment efficacy was evaluated as partial remission. Treatment should be based on the patient's physiological age, life expectancy, and tolerance to treatment. Therefore, we recommend detailed clinical evaluation and active identification of the etiology to avoid missed diagnosis and misdiagnosis.